|
Re: Holding steady
|
3
|
Resverlogix Corp.
|
Dec 22, 2018 09:37PM
|
|
Re: Novartis & Pfizer withdraw drug application in Europe
|
3
|
Resverlogix Corp.
|
Dec 23, 2018 11:01AM
|
|
Re: Third Eye Loan
|
3
|
Resverlogix Corp.
|
Dec 28, 2018 11:16AM
|
|
Re: Third Eye Loan
|
2
|
Resverlogix Corp.
|
Dec 28, 2018 12:13PM
|
|
Re: Adjudication
|
4
|
Resverlogix Corp.
|
Dec 28, 2018 02:52PM
|
|
More BET Publications and New Indications
|
1
|
Zenith Epigenetics
|
Dec 28, 2018 05:14PM
|
|
Re: Adjudication
|
4
|
Resverlogix Corp.
|
Dec 28, 2018 05:26PM
|
|
Re: Just reviewed the Sept 12, 2018 Slide Deck posted on the web site
|
1
|
Resverlogix Corp.
|
Dec 31, 2018 12:11AM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 12:24PM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 09:22PM
|
|
Re: NASH is a $35 Billion US/year market
|
3
|
Resverlogix Corp.
|
Jan 02, 2019 11:04AM
|
|
Re: 2019 Potential Events
|
3
|
Resverlogix Corp.
|
Jan 02, 2019 11:23AM
|
|
Zacks SCR Resverlogix Report 12/28/18
|
3
|
Resverlogix Corp.
|
Jan 02, 2019 11:57AM
|
|
Re: Zacks SCR Resverlogix Report 12/28/18
|
5
|
Resverlogix Corp.
|
Jan 02, 2019 12:32PM
|
|
Re: Shares to Zenith
|
4
|
Resverlogix Corp.
|
Jan 03, 2019 10:15PM
|
|
Phase 1b/2 trial expected to initiate 1Q 2019
|
7
|
Zenith Epigenetics
|
Jan 04, 2019 10:51AM
|
|
Re: Share Price
|
4
|
Resverlogix Corp.
|
Jan 04, 2019 12:07PM
|
|
Revamped website
|
4
|
Resverlogix Corp.
|
Jan 05, 2019 11:53AM
|
|
Re: Revamped website
|
4
|
Resverlogix Corp.
|
Jan 06, 2019 07:35AM
|
|
Re: Revamped website
|
5
|
Resverlogix Corp.
|
Jan 06, 2019 09:35PM
|
